Previous studies found that plasma NfL and GFAP markers are elevated in genetic FTD, with NfL outperforming GFAP in their ability to discriminate carriers from non-carriers, and in their ability to predict clinical progression [39]. This evidence concerns the gene GFAP and frontotemporal dementia.